← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
ADCBiologicJiangsu HengRui Medicine Co., L…Phase 2

Hydroxydaunomycin (Hydroxydaunomycin)

Richter Syndrome; Chronic Lymphocytic Leukemia · Richter Syndrome

#RichterSyndrome#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 95%임상시험 61상태 RECRUITING
AntibodyBristol Myers Squibbvedotin after avelumabPhase 2

Opdivo (Nivolumab, Nivolumab (Opdivo))

Solid Tumors · Anaplastic Large Cell Lymphoma, ALK-Posi

#AnaplasticLargeCellLymphomaALK-P#Antibody#Phase2#인기#항체+5
효능 ORR 100%임상시험 61상태 RECRUITING
ADCBiologicRegeneron PharmaceuticalsPhase 3

Prednisone/ prednisolone (Prednisone/ prednisolone)

Follicular Lymphoma (FL) · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 95%임상시험 61상태 RECRUITING
ADCBiologicPfizerPhase 2

Sunitinib Malate (Sunitinib Malate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 59%임상시험 61상태 RECRUITING
ADCBiologicAstellas Pharma Global Developm…Phase 3

TAS-102 (TAS-102)

Metastatic Colorectal Cancer · Gastric Cancer

#GastricCancer#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 20%임상시험 61상태 ACTIVE
CGTBiologicGlaxoSmithKlineSN-38 also augmented IL-10 …Phase 2

topotecan hydrochloride (topotecan hydrochloride)

Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Cancer

#FallopianTubeCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 95.4%임상시험 61상태 DISCONTINUED
AntibodyRochegovitecan in patients with …Preclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#인기#항체+4
효능 ORR 46.4%임상시험 60상태 ACTIVE
CGTBiologicSinobioway Cell Therapy Co., Lt…Preclinical

CD19-targeted CAR-T cells (CD19-targeted CAR-T cells)

Lymphoma · CD19

#CD19#CGT#Preclinical#인기#세포유전치료+5
효능 ORR 94%임상시험 60상태 ACTIVE
AntibodyMario Negri Institute for Pharm…Approved

Certolizumab pegol (Certolizumab pegol)

Rheumatoid Arthritis · Crohn's Disease

#CrohnsDisease#Antibody#Approved#인기#항체+4
효능 ORR 5%임상시험 60상태 ACTIVE
CGTBiologicEpicentRx, Inc.Phase 2

Checkpoint Inhibitor, Immune (Checkpoint Inhibitor, Immune)

Solid Tumor, Adult; Cancer · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase2#인기#세포유전치료+5
효능 ORR 59%임상시험 60상태 RECRUITING
CGTBiologicBellicum PharmaceuticalssPhase 2

Chimeric antigen receptor (CAR, Chimeric antigen receptor, Chimeric antigen receptor (CAR) T-cell therapy)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Phase2#인기#세포유전치료+4
효능 ORR 80.3%임상시험 60상태 RECRUITING
CGTBiologicTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
임상시험 60상태 RECRUITING
CGTBiologicTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
임상시험 60상태 RECRUITING
AntibodyGlaxoSmithKlinederuxtecan improved objecti…Phase 2

Dostarlimab (Dostarlimab)

Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase2#인기#항체+5
효능 ORR 88%임상시험 60상태 DISCONTINUED
ADCBiologicMerck Sharp & Dohme LLCPhase 1

Gemcitabine/Cisplatin II (Gemcitabine/Cisplatin II)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#인기#항체약물접합체+2
효능 ORR 72%임상시험 60상태 ACTIVE
CGTBiologicAmerican Gene Technologies Inte…sPreclinical

Gene modified therapy (Gene modified therapy)

HIV · HIV

#HIV#CGT#Preclinical#인기#세포유전치료+4
효능 ORR 41.6%임상시험 60상태 ACTIVE
CGTBiologicNational Heart, Lung, and Blood…Phase 2

Haploidentical Hematopoietic Cell Transplantation (Haploidentical Hematopoietic Cell Transplantation)

Hemoglobinopathy (Disorder); Severe Aplastic Anemia · Primary Immune Deficiency Disorders

#PrimaryImmuneDeficiencyDisorders#CGT#Phase2#인기#세포유전치료+5
임상시험 60상태 RECRUITING
CGTBiologicMedigene AGPhase 2

Lymphodepletion (Lymphodepletion)

Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer · FRα

#FR#CGT#Phase2#인기#세포유전치료+5
효능 0%임상시험 60상태 DISCONTINUED
CGTBiologicTurnstone Biologics, Corp.Phase 1

RT-01 (Oncolytic Virus Injection, Oncolytic Virus Injection(RT-01))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#CGT#Phase1#인기#세포유전치료+4
효능 ORR 28%임상시험 60상태 ACTIVE
ADCBiologicOnconic Therapeutics Inc.releasePhase 2

PARP inhibitor (PARP inhibitor)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 27.66%임상시험 60상태 RECRUITING

15 / 209 페이지

← 이전다음 →